Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI).
Denise Aysel Yardley
Consultant or Advisory Role - Novartis (U)
Linda D. Bosserman
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Nancy Walker Peacock
No relevant relationships to disclose
Anne Favret
No relevant relationships to disclose
Susan Kay Morgan
No relevant relationships to disclose
Victor M. Priego
No relevant relationships to disclose
J. David Bass
No relevant relationships to disclose
Paula L. Griner
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose
Joyce O'Shaughnessy
Consultant or Advisory Role - Genentech; Novartis